A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

NCT01864538 Phase 2 TERMINATED Results posted

The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.

Details

Lead sponsor	ImmunoGenesis
Phase	Phase 2
Status	TERMINATED
Enrolment	11
Start date	2013-05
Completion	2015-09

Conditions

• Metastatic Melanoma

Interventions

• TH-302

Primary outcomes

• Overall Survival — 1 year

Countries

United States, Canada